A phase 3 trial of MaaT Pharma’s graft-versus-host disease (GvHD) drug candidate has hit its primary endpoint, positioning the biotech to seek approval of the microbiome therapy in Europe in mid-2025.

MaaT Pharma is racing its microbiome therapy into a late-phase cancer clinical trial. Rather than take the current phase 1b to its planned conclusion, MaaT is wrapping the trial up early to accelerate ...

LYON, France--(BUSINESS WIRE)--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies ...

LYON, France--(BUSINESS WIRE)--Regulatory News: We are grateful for the confidence shown in MaaT Pharma and the support from the EIB, which is a further foundation towards the next phase of MaaT ...

In June 2025, the European Medicines Agency accepted for review the marketing authorization submission for this medicine MaaT Pharma will receive a €10.5 million upfront payment, further potential ...

The study met its primary endpoint with a significant gastrointestinal overall response rate at Day 28 of 62% and demonstrates the unprecedented efficacy of MaaT013 as third-line treatment of aGvHD ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

MaaT Pharma is charting new territory in oncology by positioning microbiome-driven therapy as a potentially promising new pillar alongside traditional treatments. In this discussion, CEO and ...

LYON, France--(BUSINESS WIRE)--$MAAT #Cancer--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader ...

IMMUNOLIFE, a Phase 2 randomized exploratory study, will evaluate the potential of MaaT033 in combination with Cemiplimab versus Best Investigator Choice (i.e.: second line) in enhancing disease ...